Sanofi nears deal to buy US firm
Boston, January 8, 2011
US biotechnology company Genzyme Corp and French drugmaker Sanofi Aventis are moving closer in their discussions about a possible acquisition, according to sources familiar with the situation.
Sanofi has offered to acquire Genzyme, a maker of drugs for rare diseases, for $18.5 billion, or $69 a share - a figure Genzyme says is too low.
According to two sources, no hard number has been placed on the table, but one source said advisers to the firm have bandied around figures in a broad $80 a share range, which would include a contingent value right (CVR) - a tradeable instrument that would give Genzyme shareholders an additional benefit if the company reaches certain milestones.
Still, it is unclear how meaningful any figure under discussion is since no agreement has been reached on what portion of it would come in the form of a CVR and how much in cash.
The value of a CVR would be discounted by investors based on their assumptions of whether Genzyme could reach its milestones. The real value of any transaction could be much lower than $80 a share.
Those milestones would most likely be tied to its experimental drug, alemtuzumab, for multiple sclerosis. Genzyme has said it expects to generate peak sales from the drug of $3.5 billion - a much higher figure than most analysts are estimating, and higher than the $700 million or so estimated by Sanofi.
Five out of six Genzyme investors questioned by Reuters said they would prefer a higher cash payment, with only a small portion coming in the form of a CVR.
According to one source, Sanofi would be willing to increase its offer by a nominal amount and include a CVR in a final deal, though the company would be unlikely to strike a deal worth $80 a share.
Genzyme's shareholders have until January 21 to tender their shares to Sanofi, which has already extended its $69 a share offer once.-Reuters
More Health & Environment Stories
- SARS virus claims one more victim in Saudi
- New support group comes to overeaters' rescue
- RAK Hospital launches urinary clinic for women
- NBAD backs Emiratis on Antarctica trip
- Cut sugar intake drastically urges WHO
- Al khaliji to fund Qatar recycling plant
- Qatar researcher in 360km breast cancer run
- New facilitator to open in DHCC
- Many countries lack capacity to prevent hearing loss
- QUIT NOW: Passive smoking hurts kids' arteries
- San Francisco to ban plastic water bottles
- GSK wins home toothpaste award for Sensodyne
- E-integration vital to GCC healthcare industry
- Fakih IVF unveils two new genetic tests
- 2 die from H1N1 in Oman
- Al Noor Hospitals targets domestic growth
- Medical panel on the way in Bahrain
- 40pc of UAE adults ‘have hypertension’
- Saudi diabetics urged to stay away from camels
- GCC readies plan to fight heart diseases
- Bahrain opens sickle cell hospital
- Hazardous waste focus for Oman summit
- Infectious viruses to be tracked by satellite in UAE
- Mafraq Hospital names new surgery chief
- Saudi health ministry seals BMJ partnership
- Need for medical simulation training highlighted
- UAE-France discuss healthcare collaboration
- Seha focus on patient centred services
- Saudi-Tokyo firms in wastewater technology JV
- Leading experts at Dubai diabetes conference